

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

**Claims 1. – 13. (Canceled)**

**Claim 14. (Currently amended)** ~~The multilaminate backing construction of claim 13~~ A multilaminate backing construction for a drug delivery device to skin comprising:

- (a) an outer layer comprising an embossable, writable and breathable material;
- (b) a multilaminate tie layer disposed on the skin proximal surface of the outer layer, wherein the tie layer comprises a secondary drug-containing reservoir; and
- (c) a base layer disposed on the skin proximal surface of the tie layer.

**Claim 15. (Currently amended)** ~~The multilaminate backing construction of claim 13~~ 14 wherein the multilaminate tie layer comprises:

- (i) a first layer disposed on the skin proximal surface of the outer layer;
- (ii) a second layer disposed on the skin proximal surface of the first layer;
- (iii) a third layer disposed on the skin proximal surface of the second layer; and
- (iv) ~~a~~ the secondary drug-containing reservoir.

**Claim 16. (Original)** The multilaminate backing construction of claim 15 wherein the first layer is ethylene-vinyl acetate copolymer (EVA) or low density polyethylene (LDPE) layer; the second layer is a polyethylene terephthalate (PET) layer; the third layer is ethylene-vinyl acetate copolymer (EVA); low density polyethylene (LDPE) layer, or a polyurethane layer.

**Claim 17. (Canceled)**

Atty. Docket No.: ARC3254R1/ALZ5033  
Serial No.: 10/646,539

Response to the Office  
Communication mailed 03/09/2006

**Claim 18. (New)** The multilaminate backing construction of claim 14 wherein the outer layer comprises a material selected from the group consisting of low density polyethylene (LDPE), medium density polyethylene (MDPE), high density polyethylene (HDPE), ultra high density polyethylene (UHDPE), polypropylene, and polyester.

**Claim 19. (New)** The multilaminate backing construction of claim 14 wherein the base layer comprises a polymeric material selected from the group consisting of polyester-polyolefin laminate, low density polyethylene (LDPE), medium density polyethylene (MDPE), high density polyethylene (HDPE), ethylene methyl acrylate copolymer (EMA), ethylene ethyl acrylate copolymer (EEA), and ethylene butyl acrylate copolymer (EBA) copolymers.

**Claim 20. (New)** The multilaminate backing construction of claim 14 wherein the multilaminate backing is part of a device for transdermal delivery of a drug and the secondary drug-containing reservoir has a polymeric matrix including an antagonist to the drug.

**Claim 21. (New)** The multilaminate backing construction of claim 14 wherein the multilaminate backing is part of a device for transdermal delivery of a drug and the secondary drug-containing reservoir has a thermoformable polymeric matrix including an antagonist to the drug, the antagonist being dispersed in the polymeric matrix but not dissolved in the polymeric matrix.

**Claim 22. (New)** The multilaminate backing construction of claim 14 wherein the multilaminate backing is part of a device for transdermal delivery of a drug and wherein the secondary drug-containing reservoir has a polymeric matrix and dispersed in the polymeric matrix is a particulate antagonist to the drug.

**Claim 23. (New)** The multilaminate backing construction of claim 14 wherein the multilaminate backing is part of a device for transdermal delivery of a drug to the skin, the secondary drug-containing reservoir includes an antagonist to the drug and wherein the outer layer controls the release of the antagonist.

Atty. Docket No.: ARC3254R1/ALZ5033  
Serial No.: 10/646,539

Response to the Office  
Communication mailed 03/09/2006

**Claim 24.** (New) The multilaminate backing construction of claim 14 wherein the outer layer is made of a material selected from the group consisting of porous, microporous, microfibrillar, spun-bonded, spun laced, track etched, rayon, wood-pulp, spun laced polyester, and coated paper product materials and combinations thereof.

**Claim 25.** (New) The multilaminate backing construction of claim 14 wherein the outer layer is made of a material selected from the group consisting of microporous, microfibrillar materials and combinations thereof.

**Claim 26.** (New) The multilaminate backing construction of claim 14 wherein the outer layer is part of a device for transdermal delivery of a drug to the skin, and the secondary drug-containing reservoir contains an antagonist to the drug, the antagonist being selected from a group consisting of naltrexone, methylnaltrexone, naloxone, nalbuphine, nalorphine, nalorphine dinicotinate, nalmefenc, nadide, levallorphan, cyclozocine and pharmaceutically acceptable salts thereof.

**Claim 27.** (New) The multilaminate backing construction of claim 14 wherein the multilaminate backing is part of a device for transdermal delivery of a drug to the skin, the secondary drug-containing reservoir includes an antagonist to the drug and wherein the outer layer is microporous and controls the release of the antagonist and the base layer is not permeable to the antagonist such that the antagonist is not delivered to the skin.

**Claim 28.** (New) The multilaminate backing construction of claim 14 wherein the multilaminate tie layer comprises:

- (i) a first layer disposed on the skin proximal surface of the outer layer;
- (ii) a second layer disposed on the skin proximal surface of the first layer;
- (iii) a third layer disposed on the skin proximal surface of the second layer; and
- (iv) a secondary drug-containing reservoir containing particles of an antagonist to a drug, the particles dispersed in a polymeric matrix in the drug-containing reservoir;

Atty. Docket No.: ARC3254R1/ALZ5033  
Serial No.: 10/646,539

Response to the Office  
Communication mailed 03/09/2006

wherein the multilaminatc backing construction is part of a device for delivery of the drug and outer layer controls release of the antagonist for deterrence against drug abuse and wherein the embossable outer layer is microporous and not laminated on a layer that is one of a pressure sensitive adhesive and a high density polyethylene such that the embossable outer layer is not permanently clear.

**Claim 29. (New)** The multilaminatc backing construction of claim 14 wherein the secondary drug-containing reservoir has a polymeric matrix and includes an antagonist that is not permeable through the base layer and wherein the outer layer is an antagonist release rate controlling layer.

**Claim 30. (New)** The multilaminatc backing construction of claim 14 wherein the tie layer does not contain pressure sensitive adhesive or high density polyethylene next to the outer layer.

**Claim 31. (New)** A multilaminatc backing construction for a drug delivery device to skin comprising:

(a) an outer layer comprising an embossable, writable and breathable microporous material, the outer layer being rate-controlling to an antagonist of a drug;

(b) a multilaminatc tie layer, the tie layer disposed on the skin proximal surface of the outer layer and including a first layer disposed on the skin proximal surface of the outer layer and at least one additional layer disposed on the skin proximal surface of the first layer, a secondary drug-containing reservoir being one of the at least one additional layer, the secondary drug-containing reservoir including a polymeric matrix with antagonist-containing particles dispersed therein, the antagonist being selected from a group consisting of naltrexone, methylnaltrexone, naloxone, nalbuphine, nalorphine, nalorphine dinicotinate, nalmefene, nadide, levallorphan, cyclozocine and pharmaceutically acceptable salts thereof; and

(c) a base layer disposed on the skin proximal surface of the tie layer, the base layer being impermeable to the antagonist preventing permeation thereof to the skin.